```json
{
"content": [
{
"type": "paragraph",
"content": "The past 12‑18 months have reshaped the Molecular Laboratory Diagnostic Kits industry trends, driven by strategic alliances, consolidation, and rapid innovation across partnerships, acquisitions, new product launches, regulatory shifts, and fresh funding. This momentum positions the market for expanded global reach and deeper integration into point‑of‑care workflows."
},
{
"type": "list",
"items": [
{
"text": "Roche and Illumina teamed up to co‑develop next‑gen sequencing‑based diagnostic panels for infectious diseases, leveraging Roche's assay expertise and Illumina's sequencing platforms.",
"level": 1
},
{
"text": "Thermo Fisher acquired biotech start‑up GenDx for $1.2 bn, expanding its portfolio of multiplex PCR kits for rare genetic disorders.",
"level": 1
},
{
"text": "BioMérieux introduced the ViroTrack™ SARS‑CoV‑2+ kit, a point‑of‑care RT‑LAMP assay delivering results in under 15 minutes, targeting decentralized testing.",
"level": 1
},
{
"text": The FDA’s revised Emergency Use Authorization framework now permits conditional approval of CRISPR‑based kits, accelerating market entry for several firms.",
"level": 1
},
{
"text": Chinese venture fund Sequoia Capital China led an $80 million Series C round for Shenzhen‑based Nucleomics, enabling construction of a new GMP‑compliant manufacturing hub in Shanghai.",
"level": 1
}
]
}
]
}
```
